Aliases & Classifications for Raynaud Disease

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 57 12 44 15 73
Raynaud's Disease 12 43
Secondary Raynaud's Phenomenon 73
Cold Fingers, Hereditary 57
Raynaud's Syndrome 12
Raynaud Phenomenon 73

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
raynaud disease:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 179600
Disease Ontology 12 DOID:10300
ICD10 33 I73.0
MeSH 44 D011928
SNOMED-CT 68 22954002
MedGen 42 C0034734
SNOMED-CT via HPO 69 263681008 266261006

Summaries for Raynaud Disease

MedlinePlus : 43 Raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. It causes the blood vessels to narrow when you are cold or feeling stressed. When this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. When the blood flow returns, the skin turns red and throbs or tingles. In severe cases, loss of blood flow can cause sores or tissue death. Primary Raynaud's happens on its own. The cause is not known. There is also secondary Raynaud's, which is caused by injuries, other diseases, or certain medicines. People in colder climates are more likely to develop Raynaud's. It is also more common in women, people with a family history, and those over age 30. Treatment for Raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as Soaking hands in warm water at the first sign of an attack Keeping your hands and feet warm in cold weather Avoiding triggers, such as certain medicines and stress NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to raynaud phenomenon and reynolds syndrome, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Raynaud Disease is RCC1 (Regulator Of Chromosome Condensation 1), and among its related pathways/superpathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and Endothelin Pathways. The drugs Cilostazol and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are abnormality of the skeletal system and raynaud phenomenon

Description from OMIM: 179600

Related Diseases for Raynaud Disease

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 raynaud phenomenon 31.9 VWF EDN1
2 reynolds syndrome 11.3
3 scleroderma, familial progressive 10.1 TOP1 EDN1
4 eisenmenger syndrome 10.0 VWF EDN1
5 collagen disease 10.0 TOP1 EDN1
6 hepatic vascular disease 10.0 VWF EDN1
7 diabetic angiopathy 10.0 VWF EDN1
8 angina pectoris 10.0 VWF EDN1
9 hepatopulmonary syndrome 10.0 VWF EDN1
10 limb ischemia 10.0 VWF EDN1
11 chronic pulmonary heart disease 10.0 PTGIR EDN1
12 portal hypertension 9.9 VWF EDN1
13 arteries, anomalies of 9.9 VWF EDN1
14 systemic scleroderma 9.9 TOP1 EDN1
15 hellp syndrome 9.8 VWF EDN1
16 diabetes mellitus 9.7
17 pulmonary hypertension 9.7 VWF PTGIR EDN1

Graphical network of the top 20 diseases related to Raynaud Disease:



Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Symptoms via clinical synopsis from OMIM:

57
Limbs:
intermittent attacks of numb and white fingers


Clinical features from OMIM:

179600

Human phenotypes related to Raynaud Disease:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924
2 raynaud phenomenon 32 HP:0030880

UMLS symptoms related to Raynaud Disease:


nausea and vomiting, constipation, fever, fatigue, angina pectoris, abdominal pain, edema, pruritus, pain, chest pain, diarrhea, headache, syncope, chronic pain, sciatica, pelvic pain, coughing, cold intolerance, icterus, vertigo/dizziness, dyspepsia, heartburn, gastrointestinal gas, symptoms, halitosis, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.17 ACOT7 CHST8 EDN1 IL1R1 PEPD PTGIR

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
3 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
5 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
7 Protective Agents Phase 4,Early Phase 1
8 Respiratory System Agents Phase 4
9 Bronchodilator Agents Phase 4
10 Fibrinolytic Agents Phase 4
11 Phosphodiesterase 3 Inhibitors Phase 4
12 Autonomic Agents Phase 4,Early Phase 1
13 Anti-Asthmatic Agents Phase 4
14 Neuroprotective Agents Phase 4,Early Phase 1
15 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
17 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
18 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
20 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Not Applicable
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Pharmaceutical Solutions Phase 4,Phase 3,Not Applicable,Early Phase 1
24
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
25
Nitrous oxide Approved, Vet_approved Phase 3,Not Applicable 10024-97-2 948
26
Tadalafil Approved, Investigational Phase 3,Phase 2,Not Applicable 171596-29-5 110635
27
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
28
Nifedipine Approved Phase 3,Early Phase 1 21829-25-4 4485
29
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
30
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
31
Prilocaine Approved Phase 3 721-50-6 4906
32
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
33
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 77-92-9 311
35
Udenafil Investigational Phase 2, Phase 3 268203-93-6 6918523
36 Fasudil Investigational Phase 3 103745-39-7
37 calcium channel blockers Phase 3,Phase 2,Early Phase 1
38 Calcium, Dietary Phase 3,Phase 2,Early Phase 1,Not Applicable
39 Antihypertensive Agents Phase 2, Phase 3,Not Applicable,Early Phase 1
40 Insulin, Globin Zinc Phase 3
41 insulin Phase 3
42 Vardenafil Dihydrochloride Phase 2, Phase 3
43 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
44 Tocolytic Agents Phase 3,Early Phase 1
45 Sildenafil Citrate Phase 2, Phase 3,Phase 3,Early Phase 1 171599-83-0
46 Citrate Phase 2, Phase 3,Phase 3,Early Phase 1
47 Protein Kinase Inhibitors Phase 3
48 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine Phase 3
49 Anticoagulants Phase 3
50 Chelating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
3 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon Recruiting NCT03639766 Phase 4 AbobotulinumtoxinA
4 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
5 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
6 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
7 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
8 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
9 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
10 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
12 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
13 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
14 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
15 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
16 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
17 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
18 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
19 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
20 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
21 Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Recruiting NCT03717961 Phase 3 BOTOX® solution;Placebo group
22 Exparel as a Nerve Block for Severe Hand Pain Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
23 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
24 Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Completed NCT00528242 Phase 2 SLx-2101;Placebo
25 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
26 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
27 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
28 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
29 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
30 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
31 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2 Alprostadil
32 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
33 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2 Cialis
34 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
35 Riociguat in Scleroderma Associated Digital Ulcers Completed NCT02915835 Phase 2 Riociguat;Placebo
36 Brentuximab Vedotin for Systemic Sclerosis Recruiting NCT03222492 Phase 1, Phase 2
37 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Active, not recruiting NCT02290613 Phase 2 Ambrisentan;Placebo
38 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
39 Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
40 MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
41 Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands Unknown status NCT01378845 Not Applicable Tracleer;Prostavasin
42 PORH and Response to Cold in Raynaud's Phenomenon. Unknown status NCT02183779 Not Applicable L-NMMA and Fluconazole dermic injection
43 Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study Unknown status NCT02642146 Calcium Channel Blockers;Phosphodiesterase Inhibitors;Endothelin receptor blocker;Prostanoids;Other vasodilator
44 Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Unknown status NCT00324181
45 Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. Completed NCT02615964
46 Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis Completed NCT02212249 Not Applicable
47 Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Completed NCT02683408 Not Applicable
48 Botulinum Toxin in the Treatment of Raynaud's Completed NCT01233999 Not Applicable botulinum toxin A
49 A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP) Completed NCT02506062 Not Applicable
50 Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis. Completed NCT01743612 Not Applicable

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: raynaud disease

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

41
Skin, Lung, Heart, Testes, Tongue, Spinal Cord, Eye

Publications for Raynaud Disease

Articles related to Raynaud Disease:

(show top 50) (show all 312)
# Title Authors Year
1
New onset acute pulmonary edema after methylergonovine given during cesarean delivery of a patient with undiagnosed Raynaud's disease. ( 30392649 )
2018
2
Vascular branches from cutaneous nerve of the forearm and hand: Application to better understanding raynaud's disease. ( 28960445 )
2018
3
Effects of Endoscopic Thoracic Sympathectomy on Raynaud's Disease. ( 29327980 )
2018
4
The importance of perfusion index monitoring in evaluating the efficacy of stellate ganglion blockage treatment in Raynaud's disease. ( 29350104 )
2018
5
Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease. ( 30397635 )
2018
6
A Review of Raynaud's Disease. ( 27311222 )
2016
7
Severe Primary Raynaud's Disease Treated with Rituximab. ( 27651971 )
2016
8
Raynaud disease. ( 24211176 )
2014
9
Xerosis cutis: a common predicament of Raynaud's disease. ( 24933844 )
2014
10
Exercise using the Wii Fit plus with a child with primary Raynaud's disease and obesity: a case report. ( 23414388 )
2013
11
The use of noninvasive angiography for digital ischemia in Raynaud's disease. ( 22711208 )
2012
12
Cervical spinal cord stimulation with 5-column paddle lead in Raynaud's disease. ( 22828684 )
2012
13
Percutaneous bipolar radiofrequency T3 sympathicotomy in Raynaud's disease -A case report-. ( 23198043 )
2012
14
Classification of Raynaud's disease based on angiographic features. ( 21704575 )
2011
15
You're the flight surgeon: Raynaud's disease. ( 21961408 )
2011
16
Intraoral telangiectasias associated with Raynaud disease: a report of two cases. ( 19907728 )
2010
17
Mayo Clinic office visit. Raynaud's disease. An interview with Kevin Moder, M.D. ( 20980938 )
2010
18
Sequential bipolar radiofrequency lumbar sympathectomy in Raynaud's disease -A case report-. ( 21057622 )
2010
19
Dynamic Doppler evaluation of the hand arteries of the patients with Raynaud's disease. ( 19238503 )
2009
20
Gradual digital lengthening with autologous bone graft and external fixation for correction of flail toe in a patient with Raynaud's disease. ( 19577729 )
2009
21
Use of Equine Derived Pericardium as a Biological Cover To Promote Closure of a Complicated Wound With Associated Scleroderma and Raynaud's Disease . ( 25902774 )
2009
22
Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. ( 18627700 )
2008
23
Oxidant/antioxidant status in patients with Raynaud's disease. ( 18463765 )
2008
24
Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. ( 17532934 )
2007
25
High resolution 3 Tesla contrast-enhanced MR angiography of the hands in Raynaud's disease. ( 16538393 )
2007
26
Raynaud's disease. Cold hands, slowed blood flow. ( 17595712 )
2007
27
Successful long-term treatment of a patient with long-standing Raynaud's disease by an extradural bupivacaine block. ( 18020090 )
2007
28
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. ( 16432094 )
2006
29
The patient with cold hands: understanding Raynaud's disease. ( 17124789 )
2006
30
Successful use of spinal cord stimulation in the treatment of severe Raynaud's disease of the hands. ( 15618807 )
2005
31
Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud's disease. ( 15769250 )
2005
32
The effects of capecitabine in Raynaud's disease: a case report. ( 15788442 )
2005
33
Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. ( 15146428 )
2004
34
Differentiation of primary and secondary Raynaud's disease by carotid arterial stiffness. ( 12651172 )
2003
35
Raynaud's disease. ( 12814733 )
2003
36
Basics of Compounding for Raynaud's Disease. ( 23979700 )
2003
37
Diabetes mellitus vs. Raynaud disease: different lung vascular bed disorders. ( 12505097 )
2002
38
Images in clinical medicine. Acute episode of Raynaud's disease. ( 12324555 )
2002
39
Adventitial stripping of the radial and ulnar arteries in Raynaud's disease. ( 12457360 )
2002
40
By the way, doctor... I am 48 and was diagnosed as having Raynaud's disease about 20 years ago. When I go outside during the winter, my fingers turn white and hurt. Is there anything new to help me? ( 11684501 )
2001
41
Acute vasospastic attack after extradural block in a patient with Raynaud's disease. ( 10825332 )
2000
42
Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. ( 10336574 )
1999
43
The cutaneous vasoconstrictor response to venous stasis is normal in subjects with primary Raynaud's disease. ( 10580877 )
1999
44
Is cryotherapy an occupational "contact" hazard for physicians with Raynaud's disease? ( 9066854 )
1997
45
Role of digital artery adrenoceptors in Raynaud's disease. ( 9546943 )
1997
46
A novel anti-microfilament antibody, anti-135 kD, is associated with Raynaud's disease, undifferentiated connective tissue disease and systemic autoimmune diseases. ( 9020409 )
1996
47
Familial aggregation of primary Raynaud's disease. ( 8670329 )
1996
48
Raynaud's disease: patient education as a primary nursing intervention. ( 8900768 )
1996
49
Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. ( 7664425 )
1995
50
Raynaud's disease: pathophysiology, diagnosis, and treatment. ( 7756043 )
1995

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.86 PTGIR VWF
2 10.49 EDN1 PTGIR
3 10.1 EDN1 PTGIR

GO Terms for Raynaud Disease

Cellular components related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Weibel-Palade body GO:0033093 8.62 EDN1 VWF

Biological processes related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome segregation GO:0007059 8.62 RCC1 TOP1

Sources for Raynaud Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....